I was also surprised it was not market sensitive. Taking onboard your detractions, there may still be a silver lining here. I'm relying on my memory here but when this generic Nuvaring from Mithra/Mayne was first floated, there was a suggestion that due to some improvement in the manufacturing/packaging, this version of the generic (Haloette) had a superior (longer) shelf life than both the original and the other generics on the market. There was the suggestion that this was part of the reason why FDA approval was held up for so long. If that is still the case, it's reasonable to assume that Haloette would perform better in the marketplace, even though late and perhaps slightly crowded.
MYX Price at posting:
35.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)